文献速递生殖医学

比较孕激素预处理卵巢刺激方案与拮抗剂方案后首次冻融胚胎移植活产率的随机对照试验

A randomized controlled trial to compare the live birth rate of the first frozen embryo transfer following the progestin-primed ovarian stimulation protocol vs. the antagonist protocol in women with an anticipated high ovarian response.
PubMed 文献 · Fertil Steril · 2024-01-23

该随机对照试验纳入784例预计高卵巢反应的不孕女性,比较PPOS方案与拮抗剂方案后首次冻融胚胎移植的活产率。意向性分析显示PPOS组活产率37.5%(147/392) vs 拮抗剂组32.7%(128/392),相对风险1.148(95%CI 0.949-1.390),两组无统计学显著差异。结论认为两种方案后首次FET的活产率相当。

要点

  • PPOS组与拮抗剂组首次FET活产率意向性分析无统计学显著差异(RR 1.148,95%CI 0.949-1.390)。
  • 符合方案分析活产率PPOS组44.5%(147/330) vs 拮抗剂组39.1%(128/327),RR 1.138(95%CI 0.950-1.364)。
  • 两组临床妊娠、持续妊娠、流产、多胎妊娠、异位妊娠及累积活产率均相当。

核心结论

  • 在预计高卵巢反应女性中,PPOS方案与拮抗剂方案后首次冻融胚胎移植的活产率相当。

研究设计与样本

  • 随机对照试验,纳入年龄<43岁、接受首个体外受精周期且窦卵泡计数>15的不孕女性。
  • 2020年6月至2021年10月共招募784例,按1:1随机分为PPOS组(n=392)和拮抗剂组(n=392)。
  • PPOS方案从卵巢刺激开始至扳机日每日给予甲羟孕酮10 mg;拮抗剂方案从刺激第6天至扳机日每日给予拮抗剂0.25 mg。
  • 女性及医生无法设盲,但生物统计师对分组设盲。

主要发现

  • PPOS组62例(62/392,15.8%)和拮抗剂组65例(65/392,16.6%)因无可移植胚胎或随机后6个月内无FET而取消或推迟胚胎移植。
  • 意向性分析首次FET活产率:PPOS组37.5%(147/392) vs 拮抗剂组32.7%(128/392),相对风险1.148(95%CI 0.949-1.390)。
  • 符合方案分析首次FET活产率:PPOS组44.5%(147/330) vs 拮抗剂组39.1%(128/327),相对风险1.138(95%CI 0.950-1.364)。
  • 两组人口学特征及获卵数、受精数、卵裂胚胎数、第3天优质胚胎数、囊胚形成数、冷冻胚胎或囊胚数均相似。
  • 两组临床妊娠、持续妊娠、流产、多胎妊娠、异位妊娠及累积活产率均相当。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the live birth rate of the first frozen embryo transfer (FET) after ovarian stimulation by the progestin-primed ovarian stimulation (PPOS) protocol vs. the antagonist protocol in women with an anticipated high ovarian response who were undergoing in vitro fertilization. DESIGN: Randomized controlled trial. SETTING: A tertiary assisted reproduction center. PATIENTS: Women with infertility aged <43 years undergoing the first in vitro fertilization cycle and having antral follicle count of >15. INTERVENTIONS: Medroxyprogesterone 10 mg daily was given from the start of ovarian stimulation until the day of ovulation trigger in the PPOS protocol. In the antagonist protocol, an antagonist 0.25 mg daily was given from the sixth day of ovarian stimulation until the day of ovulation trigger. Blinding was not possible for women or physicians but the biostatistician was blinded to the group assignment. MAIN OUTCOME MEASURE: Live birth rate of the first FET cycle. RESULTS: A total of 784 women were recruited from June 2020 and October 2021 and assigned randomly in a 1:1 ratio into two groups: PPOS group (n = 392) and antagonist group (n = 392). Embryo transfer was either cancelled or postponed in 62 women (62/392, 15.8%) in the PPOS group and 65 (65/392, 16.6%) in the antagonist group because of no transferable embryos or no FET within 6 months after randomization. The two groups were similar in demographic characteristics and the numbers of oocytes obtained or fertilized, cleaving embryos, good-quality embryos at day 3, blastocysts developed, and embryos or blastocysts frozen. There was no statistically significant difference in the live birth rate of the first FET cycle between the PPOS and antagonist groups on the basis of both the intention-to-treat analysis (37.5.0% [147/392] vs. 32.7% [128/392]; relative risk, 1.148 [95% confidence interval, 0.949-1.390]) and per-protocol analysis (44.5% [147/330] vs. 39.1% [128/327]; relative risk, 1.138 [95% confidence interval, 0.950-1.364]). Both groups showed comparable clinical pregnancy, ongoing pregnancy, miscarriage, multiple pregnancy, ectopic pregnancy, and cumulative live birth rates. CONCLUSION: The live birth rates of the first FET following the PPOS and antagonist protocols were comparable in women with an anticipated high ovarian response. CLINICAL TRIAL REGISTRATION NUMBER: NCT04414761 (ClinicalTrials.gov).

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Chen ZQ, Ai A, Zhang Y, et al. A randomized controlled trial to compare the live birth rate of the first frozen embryo transfer following the progestin-primed ovarian stimulation protocol vs. the antagonist protocol in women with an anticipated high ovarian response. Fertil Steril. 2024. PMID: 38272383. doi:10.1016/j.fertnstert.2024.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。